ACTIVE_NOT_RECRUITING

Effort During Resistance Training in Type 2 Diabetes

Conditions

Type2 Diabetes Mellitus Resistance training Degree of effort Glycemic control Continuous glucose monitoring

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this study the primary aims are to investigate the effect of resistance exercise training with different degrees of effort on glycemic control and psychological variables in individuals living with type 2 diabetes mellitus. As a secondary aim, investigate adherence and dropout rates and reasons for dropping out and adhering or not to the protocols.

Official Title

The Effect of Perceived Effort in Resistance Training on Glycemic Control and Psychological Responses in Individuals Living With Type 2 Diabetes Mellitus: a Randomized-controlled, Parallel Group, Clinical Trial

Quick Facts

Study Start:2024-09-10

Study Completion:2026-02-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06497842

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Living with type 2 diabetes mellitus	* Have a significant cognitive impairment, * Are non-ambulatory, * Have lower extremity amputation, * Have renal failure, * Have liver disease, * Have uncontrolled hypertension (\>160 mmHg systolic and/or \>100 mmHg diastolic), * Have unstable cardiovascular disease, * Have a history of severe cardiovascular problems, * Have decompensated heart failure, * Have uncontrolled arrhythmias, * Have severe pulmonary hypertension (mean pulmonary arterial pressure \>55 mm Hg), * Have severe and symptomatic aortic stenosis, * Have acute myocarditis, endocarditis, or pericarditis, * Have aortic dissection, * Have Marfan syndrome, * Have unrepaired aortic aneurysm, * Have proliferative diabetic retinopathy, * Have rapidly progressive terminal illness, * Are unable to perform resistance exercise to due preexisting musculoskeletal conditions (e.g., joint pain, chronic injury or tendinopathy), * Are under biguanide (metformin) treatment, but are taking for less than 3 months, * Have taken drugs known to increase the risk of tendon disorders (e.g., tendinopathy and tendon rupture) within the last 6 months. These drugs include, but may not be limited to: fluoroquinolones, glucocorticoids, aromatase inhibitors, anabolic steroids, antiretrovirals, isotretinoin, cephalexin, rituximab, sitagliptin, cephalosporins, azithromycin, and sulfonamides. * Are pregnant or trying to become pregnant during the study, * Are prisoners, * Are persons that require a legally authorized representative. * Being subjected to recent surgeries for which resistance training is not recommended, * Have symptomatic hernias, * Have acute illness, * Have recent fractures, or other injuries until resolved.

Inclusion Criteria

Exclusion Criteria

* Living with type 2 diabetes mellitus

* Have a significant cognitive impairment,
* Are non-ambulatory,
* Have lower extremity amputation,
* Have renal failure,
* Have liver disease,
* Have uncontrolled hypertension (\>160 mmHg systolic and/or \>100 mmHg diastolic),
* Have unstable cardiovascular disease,
* Have a history of severe cardiovascular problems,
* Have decompensated heart failure,
* Have uncontrolled arrhythmias,
* Have severe pulmonary hypertension (mean pulmonary arterial pressure \>55 mm Hg),
* Have severe and symptomatic aortic stenosis,
* Have acute myocarditis, endocarditis, or pericarditis,
* Have aortic dissection,
* Have Marfan syndrome,
* Have unrepaired aortic aneurysm,
* Have proliferative diabetic retinopathy,
* Have rapidly progressive terminal illness,
* Are unable to perform resistance exercise to due preexisting musculoskeletal conditions (e.g., joint pain, chronic injury or tendinopathy),
* Are under biguanide (metformin) treatment, but are taking for less than 3 months,
* Have taken drugs known to increase the risk of tendon disorders (e.g., tendinopathy and tendon rupture) within the last 6 months. These drugs include, but may not be limited to: fluoroquinolones, glucocorticoids, aromatase inhibitors, anabolic steroids, antiretrovirals, isotretinoin, cephalexin, rituximab, sitagliptin, cephalosporins, azithromycin, and sulfonamides.
* Are pregnant or trying to become pregnant during the study,
* Are prisoners,
* Are persons that require a legally authorized representative.
* Being subjected to recent surgeries for which resistance training is not recommended,
* Have symptomatic hernias,
* Have acute illness,
* Have recent fractures, or other injuries until resolved.

Contacts and Locations

Principal Investigator

Flavio De Castro Magalhaes, PhD

PRINCIPAL_INVESTIGATOR

Assistant Professor

Study Locations (Sites)

UNM Exercise Physiology Lab

Albuquerque, New Mexico, 87131-0001

United States

Collaborators and Investigators

Sponsor: University of New Mexico

Flavio De Castro Magalhaes, PhD, PRINCIPAL_INVESTIGATOR, Assistant Professor

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-10

Study Completion Date2026-02-01

Study Record Updates

Study Start Date2024-09-10

Study Completion Date2026-02-01

Terms related to this study

Keywords Provided by Researchers

Resistance training
Degree of effort
Glycemic control
Continuous glucose monitoring

Additional Relevant MeSH Terms

Type2 Diabetes Mellitus